Cagrilintide Dose Escalation Studies Phase 2 trials evaluated multiple cagrilintide doses to identify the optimal balance between efficacy and tolerability: 0.3 mg weekly Minimal efficacy, excellent tolerability 0.6 mg weekly Moderate effects, good tolerability 1.2 mg weekly Strong efficacy, acceptable side effects 2.4 mg weekly Optimal efficacy-tolerability balance 4.5 mg weekly Excessive GI side effects outweighed benefits The 2.4 mg weekly dose emerged as the standard in phase 3 trials, providing substantial metabolic benefits while maintaining an acceptable side effect profile[6]
Therapeutically, BPC 157 works by encouraging the body's natural cellular regeneration, aiding in tissue repair, reducing inflammation, and fostering an optimal environment for recovery
And we've already had immense success on orthopedic injuries
Provided herein are otic formulations or compositions that ameliorate or lessen otic disorders described herein
This work was supported by VA-merit BX002086 (to P.D.), DK088902 (to A.B.S.) and BX002761 (to A.B.S.)